

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

IFW

Application : <u>09/980291</u>	Examiner : <u>Saeed</u>	GAU : <u>1626</u>
From : <u>Tu</u>	Location : IDC FMF <u>(FDC)</u>	Date : <u>1-21-05</u>
Tracking # : <u>1273864</u>		Week Date : <u>12-8-03</u>

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	<u>11-27-01</u>	
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input checked="" type="checkbox"/> SPEC	<u>11-27-01</u>	

[RUSH] MESSAGE: Please verify

In the Foreign Drawings dated 11-27-01 Figure 1A-22 appears but  
on Page 29 of the specification submitted on 11-27-01 the  
description describes Tabler I through V. There two appear should  
agree.

Thank You  
Tu

[XRUSH] RESPONSE: You are really splitting hairs here,  
but since you have created this RUSH, I have  
amended the SPEC at p. 29.

INITIALS: DGO

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.  
 REV 10/04

Figure 11: Assaying of the total intracellular glutathione in quiescent PBMCs, treated 24 hours before with NAC, MEA or I-152.

Figure 12: Antiviral activity of the I-152 derivatives (I-176 is cytotoxic at the dose tested).

Figure 13: Intracellular concentration of GSH in MDMs infected or not infected *in vitro* with the reference strain with macrophage tropism HIV-1/Ba-L, and treated or not treated with the compound I-152.

Figure 14: Effects of the compound I-152 on the intracellular concentration of GSH and the synthesis of TNF- $\alpha$  in MDMs stimulated *in vitro* with a bacterial lipopolysaccharide (LPS; 1  $\mu$ g/ml) and IFN- $\gamma$  (100 IU/ml).

Figure 15: Intracellular concentration of GSH in spleen macrophages after or not after treatment with I-152. The intracellular concentration of GSH in untreated human spleen macrophages is  $22 \pm 2$   $\mu$ M.

Figure 16: Intracellular concentration of GSH in spleen macrophages infected or not infected *in vitro* with the reference strain with macrophage tropism HIV-1/Ba-L.

Figure 17: Effects of I-152 on the anti-HIV activity of AZT in MDMs infected with the HIV-1/Ba-L strain.

Figure 18 (Table I): Comparison of the antiviral activities of NAC, MEA and I-152 in MDM cultures infected with 10 000 TCID<sub>50</sub>s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Figure 19 (Table II): Effects of the m.o.i. on the antiviral activity of I-152: 50% effective doses.

Figure 20 (Table III): Antiviral activity of I-152 in spleen MDMs infected with 10 000 TCID<sub>50</sub>s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Figure 21 (Table IV): Comparison of the antiviral activities of I-152 and its S-acylated analogues in MDM cultures infected with 10 000 TCID<sub>50</sub>s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Figure 22 (Table V): Comparison of the antiviral activities of I-152 and its variously S-acylated (N-isobutyryl) derivatives in MDM cultures infected with 10 000

09980291-112701

DGO  
12-5-05